UY25873A1 - Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos - Google Patents

Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos

Info

Publication number
UY25873A1
UY25873A1 UY25873A UY25873A UY25873A1 UY 25873 A1 UY25873 A1 UY 25873A1 UY 25873 A UY25873 A UY 25873A UY 25873 A UY25873 A UY 25873A UY 25873 A1 UY25873 A1 UY 25873A1
Authority
UY
Uruguay
Prior art keywords
compounds
useful
halogen
phenyl
opiaceous
Prior art date
Application number
UY25873A
Other languages
English (en)
Inventor
Alan John Pettman
Graham Lunn
Stephen Paul
Robert James Crook
Bernard Joseph Banks
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828485.4A external-priority patent/GB9828485D0/en
Priority claimed from GBGB9912425.7A external-priority patent/GB9912425D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY25873A1 publication Critical patent/UY25873A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de fórmula (I), representada en la figura 1, así como sus sales y profármacos , donde: Ar represanta un fenilo opcionalmente benzo-condensado o un anillo heteroarilo de 5 a 6 miembros; R1 cuando se toma solo, es H, halógeno, NO2, NH2, NY2WY1, HeT1, AD, CO2R7, C(O)R8, C(=NOH)R8 u OE; R2 cuando se toma solo es H o halógeno; X es halógeno, alquilo, alcoxi, haloalquilo o haloalcoxi; n es 0, 1 o 2; q es 0 o 1; entre otras posibilidades R5 y R6 o R7 pueden tomarse junto a los átomos de carbono a los que están unidos para formar un anillo cicloalquilo C3-8; R6, R7, R9 y R10 cuando se toman por separado son H. También se incluyen procedimientos para la preparación es estos compuestos. Ejemplos de compuestos de fórmula general (I): N-{3-[6-metil-3-(3-fenilrpopil)-3-azabiciclo[3.1.0]hex-6-il]fenil}metansulfonamida; N-{3-[3-(3-ciclohexilpropil)-6-metil-3-azabiciclo[3.1.0]hex-6-il]fenil}-1-etanosulfonamida; entre otros. Estos compuestos son de utilidad como agentes de unión a opiáceos útiles en el tratamiento de afecciones mediadas por receptores opiáceos (mu, kappa, o delta).
UY25873A 1998-12-23 1999-12-22 Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos UY25873A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9828485.4A GB9828485D0 (en) 1998-12-23 1998-12-23 Compounds useful in therapy
GBGB9912425.7A GB9912425D0 (en) 1999-05-27 1999-05-27 Compounds useful in therapy
US09/467,871 US6313312B1 (en) 1998-12-23 1999-12-20 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy

Publications (1)

Publication Number Publication Date
UY25873A1 true UY25873A1 (es) 2001-08-27

Family

ID=27269601

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25873A UY25873A1 (es) 1998-12-23 1999-12-22 Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos

Country Status (33)

Country Link
US (3) US6313312B1 (es)
EP (1) EP1140828B1 (es)
JP (1) JP3553886B2 (es)
CN (1) CN1192021C (es)
AP (1) AP1852A (es)
AT (1) ATE335725T1 (es)
AU (1) AU761574B2 (es)
BG (1) BG65402B1 (es)
BR (1) BR9916584A (es)
CA (1) CA2356300C (es)
CY (1) CY1106445T1 (es)
CZ (1) CZ20012299A3 (es)
DE (1) DE69932738T2 (es)
DK (1) DK1140828T3 (es)
DZ (1) DZ2962A1 (es)
EA (1) EA004672B1 (es)
ES (1) ES2274646T3 (es)
HK (1) HK1041698B (es)
HR (1) HRP20010477B1 (es)
HU (1) HUP0104816A3 (es)
ID (1) ID28981A (es)
IL (1) IL142697A0 (es)
IS (1) IS2467B (es)
MA (1) MA25035A1 (es)
NO (1) NO321658B1 (es)
NZ (1) NZ511234A (es)
OA (1) OA11727A (es)
PL (1) PL348453A1 (es)
SI (1) SI1140828T1 (es)
SK (1) SK8772001A3 (es)
TW (1) TWI244481B (es)
UY (1) UY25873A1 (es)
WO (1) WO2000039089A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
JP4155522B2 (ja) * 2001-10-22 2008-09-24 ファイザー・プロダクツ・インク オピオイド受容体アンタゴニストとしての３−アザビシクロ（３．１．０）ヘキサン誘導体
MXPA05000434A (es) 2002-07-08 2005-04-19 Ranbaxy Lab Ltd Derivados de hexano [3.1.0] azabiciclo 3,6-disustituido utiles como antagonistas de receptor muscarinico.
US7265147B2 (en) * 2002-07-31 2007-09-04 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
DE60231341D1 (de) * 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409217A (pt) * 2003-04-09 2006-03-28 Pharmacia & Upjohn Co Llc derivados e análogos antimicrobianos da [3.1.0]bicicloexilfeniloxazolidinona
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100436414C (zh) * 2003-04-11 2008-11-26 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的氮杂双环衍生物
WO2004089908A2 (en) * 2003-04-14 2004-10-21 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives
MXPA06004278A (es) * 2003-10-16 2006-06-28 Pfizer Prod Inc Preparacion de derivados de 3-azabiciclo [3.1.0]hexano.
MX2007002136A (es) * 2004-09-01 2007-04-02 Pfizer Prod Inc Antagonistas amino azabiciclicos del receptor 3 de la histamina.
WO2006113458A1 (en) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
US20080319043A1 (en) * 2005-05-03 2008-12-25 Mohammad Salman 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
US7799815B2 (en) * 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
GB0716632D0 (en) * 2007-08-24 2007-10-03 Glaxo Group Ltd Compounds
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7691878B2 (en) * 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029257A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Disubstituted alkyl-8-azabicyclo [3.2.1.] octane compounds as mu opioid receptor antagonists
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
JP2013542929A (ja) 2010-09-28 2013-11-28 パナセア バイオテック リミテッド 新規ビシクロ環化合物
JP6041886B2 (ja) 2011-11-07 2016-12-14 スノヴィオン ファーマシューティカルズ インコーポレイテッドＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． オピオイド受容体の調節物質およびそれを含む薬学的組成物
AU2014354085B2 (en) 2013-11-20 2018-04-26 Ube Corporation Novel 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purposes
WO2015117146A1 (en) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Beta-substituted gamma-amino acids and analogs as chemotherapeutic agents
EP3102195B1 (en) 2014-02-03 2021-10-06 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents
CN104177284B (zh) * 2014-08-01 2016-08-24 常州大学 合成3-氮杂二环[3,1,0]己基-1-甲醛的方法
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
EP3299357A4 (en) * 2015-05-20 2018-11-14 Sanwa Kagaku Kenkyusho Co., Ltd. Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof
WO2017024009A1 (en) 2015-08-03 2017-02-09 Quadriga Biosciences, Inc. Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
WO2017121692A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte sulfamide und ihre verwendung
CA3054122A1 (en) 2017-03-02 2018-09-07 Sanwa Kagaku Kenkyusho Co., Ltd. Therapeutic agent for alcohol use disorders
JP7218306B2 (ja) * 2017-05-15 2023-02-06 コグニション セラピューティクス インク． 神経変性疾患を治療するための組成物
CN107501272B (zh) * 2017-09-05 2020-03-31 中国药科大学 咪唑并异吲哚类ido1抑制剂、其制备方法及应用
CN111989327A (zh) 2018-02-05 2020-11-24 奥克梅斯公司 用于治疗疼痛的化合物
CN112939844B (zh) * 2019-12-10 2023-02-03 华东师范大学 一种多取代四氢咔唑及其衍生物及其合成方法和应用
CN110938036A (zh) * 2019-12-24 2020-03-31 中国药科大学 一种4-碘-1h-咪唑的制备方法
JP2023524547A (ja) * 2020-05-07 2023-06-12 小野薬品工業株式会社 Ｋｄｍ５阻害作用を有する３－アザビシクロ（３．１．０）ヘキサン誘導体およびその医薬用途
CN112300002A (zh) * 2020-10-26 2021-02-02 安徽工业大学 一种5-硝基丹皮酚及5-硝基丹皮酚腙的制备方法
CN114057627B (zh) * 2022-01-18 2022-04-01 南京桦冠生物技术有限公司 一种丙型肝炎及新冠药物中间体及其盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB872300A (en) * 1956-10-26 1961-07-05 Wellcome Found Improvements in and relating to new derivatives of azabicyclohexane and the manufacture thereof
US3065230A (en) * 1959-03-16 1962-11-20 Burroughs Wellcome Co Azabicyclohexanes and method of preparing them
GB948730A (en) * 1959-04-08 1964-02-05 Wellcome Found Substituted cyclopropanes and related compounds
PH24752A (en) 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy

Also Published As

Publication number Publication date
MA25035A1 (fr) 2000-07-01
NO20013148L (no) 2001-08-23
DE69932738T2 (de) 2007-08-09
CY1106445T1 (el) 2011-10-12
IS2467B (is) 2008-12-15
ES2274646T3 (es) 2007-05-16
TWI244481B (en) 2005-12-01
HRP20010477A2 (en) 2002-08-31
OA11727A (en) 2004-11-08
AU761574B2 (en) 2003-06-05
US6313312B1 (en) 2001-11-06
EA004672B1 (ru) 2004-06-24
HUP0104816A2 (hu) 2002-04-29
SK8772001A3 (en) 2002-03-05
BR9916584A (pt) 2001-10-16
WO2000039089A1 (en) 2000-07-06
HK1041698B (zh) 2005-09-02
JP2002533440A (ja) 2002-10-08
SI1140828T1 (sl) 2007-02-28
CN1331679A (zh) 2002-01-16
NO321658B1 (no) 2006-06-19
ID28981A (id) 2001-07-19
AU1069800A (en) 2000-07-31
CZ20012299A3 (cs) 2001-12-12
EP1140828B1 (en) 2006-08-09
US7049444B2 (en) 2006-05-23
HUP0104816A3 (en) 2002-06-28
AP1852A (en) 2008-05-29
BG105711A (en) 2002-02-28
US20020072616A1 (en) 2002-06-13
DE69932738D1 (de) 2006-09-21
EA200100417A1 (ru) 2001-12-24
JP3553886B2 (ja) 2004-08-11
HRP20010477B1 (en) 2007-03-31
NO20013148D0 (no) 2001-06-22
US20030013875A1 (en) 2003-01-16
IL142697A0 (en) 2002-03-10
EP1140828A1 (en) 2001-10-10
DK1140828T3 (da) 2006-12-11
ATE335725T1 (de) 2006-09-15
CA2356300C (en) 2008-12-30
CN1192021C (zh) 2005-03-09
IS5922A (is) 2001-04-20
AP2001002185A0 (en) 2001-06-30
HK1041698A1 (en) 2002-07-19
BG65402B1 (bg) 2008-06-30
DZ2962A1 (fr) 2004-03-15
NZ511234A (en) 2003-09-26
PL348453A1 (en) 2002-05-20
CA2356300A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
UY25873A1 (es) Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos
MY147730A (en) Metabotropic glutamate receptor antagonists
DK0885210T5 (da) Tricykliske forbindelser med bindingsaffinitet for melatoninreceptorer, deres fremstilling og anvendelse
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
WO2006021655A3 (fr) Dérivés doxopiperidine, leur préparation et leur application en thérapeutique
NZ514873A (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
HUP0300693A2 (hu) Eljárás epotilon-analógok és -intermedierek előállítására
GB9423968D0 (en) Resolution
PE58399A1 (es) Atropisomeros de 3-aril-4(3h)-quinazolinonas
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
MXPA04000454A (es) Derivados de 2-pirrolidona como agonistas de prostanoides.
CO4650117A1 (es) Derivados de bencilsulfuro y proceso para su produccion .
ID21568A (id) Penggunaan baru untuk turunan 1,3-propanadiol
RS20100169A (en) INTERMEDIATES FOR DIOXAN-2-ALKYLCARBAMATE
CO5031250A1 (es) Compuesto farmaceutico
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
CO5560557A2 (es) Derivados de indol como inhibidores de cox-ii
ES2038678T3 (es) Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos.
CO4990932A1 (es) Derivados de 2,1,3-benzotiadiazol y proceso para su preparacion
CO5550437A2 (es) Compuestos quimicos
AR072118A1 (es) Derivados de pirrolidina como antagonistas de receptor de nk2
PE20060584A1 (es) Derivados de piridina como antagonistas de receptores de cannabinoides cb1 y procedimiento de preparacion
PE20020194A1 (es) 2,3,7,8,9,10,11,12-OCTAHIDROAZEPINO[4,5-b]PIRANO[3,2-e)INDOLES SUSTITUIDOS
NZ504316A (en) Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090206